Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzastaurin for prevention of arterial events in vascular Ehlers-Danlos syndrome
2021-006574-23Phase 3Active
- Sponsor
- Aytu BioPharma
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Vascular Ehlers-Danlos syndrome (VEDS) comparing Enzastaurin with Placebo (2 arms). Primary endpoint: Time to intervention for arterial event or arterial-event-related mortality. Started Apr 2022; status: active.
02
Drugs
enzastaurin
03
Conditions
Vascular Ehlers-Danlos syndrome (VEDS)
Beyond the preview
Go deeper on 2021-006574-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006574-23.